25
JAN
2016

NW Bio Presenting At Phacilitate Immunotherapy World Forum

Posted By :
Comments : Off
BETHESDA, MD, January 25, 2016 – Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) (“NW Bio”), a U.S. biotechnology company developing DCVax® personalized immune therapies for operable and inoperable solid tumor cancers, announced today that CEO Linda Powers will chair the morning plenary session and present at the Phacilitate Immunotherapy World Forum on Tuesday, January 26, 2016, at the Grand Hyatt Hotel in Washington DC. The plenary...
Read More
08
JAN
2016

NW Bio Issues Statement on Adverse Market Conditions And NW Bio Stock Decline

Posted By :
Comments : Off
Sees Impact of Global Market Concerns; Reiterates Encouraging Clinical Data   BETHESDA, MD, January 8, 2016 – Northwest Biotherapeutics (NASDAQ: NWBO) (“NW Bio”), a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today issued the following statement addressing the sharp decline in the Company’s stock: Global markets are experiencing serious concerns, many biotech companies’ stocks have...
Read More
25
DEC
2015

NW Bio Announces Closing Of Registered Direct Offering of $12.6 Million

Posted By :
Comments : Off
BETHESDA, Md., December 24, 2015 – Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced the closing of its previously-announced registered direct placement with healthcare focused institutional investors, for gross proceeds of $12.6 million on the terms previously announced. H.C. Wainwright & Co., LLC acted as the...
Read More
23
DEC
2015

NW Bio Announces a Registered Direct Offering of $12.6 Million

Posted By :
Comments : Off
BETHESDA, Md., December 23, 2015 – Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has entered into definitive agreements with healthcare focused institutional investors for a registered direct offering with gross proceeds of $12.6 million.  In the offering, the Company is selling an aggregate of 3.5 million...
Read More
21
DEC
2015

NW Bio Announces Annual Meeting Results, Re-Election of Directors

Posted By :
Comments : Off
BETHESDA, MD, December 21, 2015 – Northwest Biotherapeutics (NASDAQ: NWBO) (“NW Bio”), a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today the results of its 2015 Annual Shareholder Meeting, held on Friday, December 18, 2015.  There were three matters subject to a shareholder vote:  the re-election of Linda Powers and Dr. Navid Malik as Directors for 3-year terms, and the...
Read More